Client News

Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies

22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an … Continue reading “Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies”

By Optimum

DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables

TURKU, Finland, May 21, 2019 /PRNewswire/ — DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family … Continue reading “DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables”

By Optimum

Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)

Secure supply and first vial presentation of a pivotal drug for acute promyelocytic leukaemia FARNBOROUGH, England, May 20, 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with … Continue reading “Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH